15202 A phase 3 study of 0.045% tazarotene lotion for once-daily treatment of moderate to severe acne vulgaris

Abstract

Tazarotene is a topical retinoid for acne vulgaris treatment. Current gel/foam/cream formulations can cause irritation, limiting their use. A novel tazarotene 0.045% lotion formulation was developed utilizing polymeric emulsion technology, providing uniform distribution of active drug/hydrating excipients. In this phase 3, double-blind, randomized, vehicle-controlled, 12-week study, eligible patients aged ≥9 years with moderate to severe acne (n = 813) were randomized (1:1) to receive once-daily tazarotene 0.045% lotion or vehicle.